Andrew Haydon

Adj Assoc Prof

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2015 2024

Research Output 2002 2019

3 Citations (Scopus)

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 others, Dummer, R., Kirkwood, J. M. & Long, G. V., 1 May 2019, In : The Lancet Oncology. 20, 5, p. 701-710 10 p.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., Hatzimihalis, A., Henderson, M. A., Shackleton, M., Haydon, A., Mar, V., Gyorki, D. E., Oudit, D., Dawson, M. A., Hicks, R. J., Lorigan, P. & 4 others, McArthur, G. A., Marais, R., Wong, S. Q. & Dawson, S. J., 1 May 2019, In : Annals of Oncology. 30, 5, p. 804-814 11 p.

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. JM. & 12 others, Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P. C., Lupinacci, R., Krepler, C., Ibrahim, N., Kicinski, M., Marreaud, S., van Akkooi, A. C., Suciu, S. & Robert, C., 1 Jul 2019, In : European Journal of Cancer. 116, p. 148-157 10 p.

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study

Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., Yip, D., Lee, M., Tran, B., Rangiah, D., Burge, M., Goldstein, D., Singh, M., Skinner, I., Faragher, I., Croxford, M., Bampton, C. & 14 others, Haydon, A., Jones, I. T., S Karapetis, C., Price, T., Schaefer, M. J., Ptak, J., Dobbyn, L., Silliman, N., Kinde, I., Tomasetti, C., Papadopoulos, N., Kinzler, K., Volgestein, B. & Gibbs, P., 1 Apr 2019, In : Gut. 68, 4, p. 663-671 9 p.

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Iveson, T. J., Kerr, R. S., Saunders, M. P., Cassidy, J., Hollander, N. H., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Scudder, C., Boyd, K. A., Briggs, A., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Dhadda, A. S. & 16 others, Harrison, M., Falk, S., Raouf, S., Rees, C., Olesen, R. K., Propper, D., Bridgewater, J., Azzabi, A., Farrugia, D., Webb, A., Cunningham, D., Hickish, T., Weaver, A., Gollins, S., Wasan, H. S. & Paul, J., 1 Apr 2018, In : Lancet Oncology. 19, 4, p. 562-578 17 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access